Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study


Phase N/A Results N/A

Summary of Purpose

The three-year cumulative risk of a recurrent stroke, dependent on aetiology, is up to 25 per cent. At present, preventing recurrence relies on a broad approach to reduce risk factors associated with atherosclerosis, heart disease and metabolic disorders. However, more specific interventions, such as anticoagulation and surgery or stenting, need aetiologic information. BIOSIGNAL aims to determine where the most...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 May 2016.

1 Sep 2014 17 Oct 2014 1 Sep 2017 1 Sep 2017 1 May 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Probability Sample